Revisited 2026 evidence is unlikely to change routine care yet for teens with inflammatory acne because improvement is gradual, similar drugs work about as well, and cost can limit access. Clascoterone 1% cream (Winlevi) is a topical androgen-receptor inhibitor, meaning it blocks androgen signals in skin that drive oil and breakouts. Drugs.com FDA history records first approval on August 26, 2020 for acne vulgaris in patients 12 years and older, according to Drugs.com FDA history. An August 2026 narrative review searched PubMed/MEDLINE through April 2026 and found twice-daily use lowers inflammatory and noninflammatory counts, with benefit sustained up to 12 months.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 2026 review confirmed
- Why care is unlikely to shift for teens
- Irritation and hormone effects to watch
- Making twice-daily treatment work
What the 2026 review confirmed
Pooled Phase 3 data focus on facial acne treated twice daily for 12 weeks. Clascoterone cut inflammatory lesions by a mean of 19.7 versus 14.0 for vehicle, or 46.2% versus 32.5%, with total lesions down 40.0 versus 26.1, as summarized in the Pharmaceuticals narrative review, described in Pharmaceuticals narrative review.
The August 2026 review concluded the same twice-daily regimen keeps counts down through longer follow-up without new tolerability signals. For teens, that matters because red, tender bumps drive pain, marks, and picking. It does not promise fast or complete clearance.
Why care is unlikely to shift for teens
Trial success rates were modest. Two identical 12-week trials in 1,440 patients reported IGA success of 18.4% versus 9.0% and 20.3% versus 6.5% against vehicle, according to MedEsthetics reporting on JAMA Dermatology.
A 2024 systematic review and meta-analysis reported by DermNet found no significant 12-week efficacy difference among clascoterone, trifarotene, and tazarotene for moderate-to-severe acne. The 2024 American Academy of Dermatology acne guidelines found high certainty that benefit exceeds risk but gave only a conditional recommendation because high current cost may impair equitable access, stated in JAAD acne guidelines.
Irritation and hormone effects to watch
Label information shows mainly local effects. The U.S. National Library of Medicine DailyMed label lists erythema in 11-13%, scaling or dryness in 9-12%, and pruritus near 5%, often similar to vehicle, detailed in DailyMed Winlevi label.
The same label notes reversible HPA-axis suppression in 1 of 20 adults and 2 of 22 adolescents. Teens need monitoring for adrenal symptoms such as unusual fatigue, weakness, nausea, or dizziness. Reduce frequency when irritation occurs and contact the prescriber for guidance.
Making twice-daily treatment work
Benefit grows with persistence. Healio reporting on the long-term extension found improvement in 19.9% at 12 weeks rising to about 30.2% facial success at 12 months. Clinicians often pair thin-layer twice-daily use with a retinoid rather than expect rapid clearance.
- Apply a thin layer twice daily exactly as prescribed
- Use with a retinoid only when the clinician directs it
- Track tender red bumps for at least 12 weeks before judging
- Pause and call for burning, peeling, swelling, or adrenal symptoms
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Why the Findings May Not Change Acne Care Yet for Teens With Inflammatory Acne
- Topical Clascoterone Evidence Revisited in 2026: Who Was Studied and Who Was Not for Teens With Inflammatory Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: Who Was Studied and Who Was Not for Teens With Inflammatory Acne